QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

RLAY

QT65Relay Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
15.88
+0.32+2.06%
OverviewShort InterestFilings
RLAYQT65Relay Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
15.88+2.06%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-3.89
Insider Own22.46%
Shs Outstand215.56M
Perf Week11.52%
Market Cap2.72BForward P/E-EPS next Y-1.60Insider Trans-0.07%Shs Float-Perf Month31.57%
Enterprise Value2.55BPEG-EPS next Q-0.41Inst Own-Short Float-Perf Quarter58.80%
Income-265245044.00P/S255.06EPS this Y60.17%Inst Trans-Short Ratio-Perf Half Y87.26%
Sales10.68MP/B4.36EPS next Y-3.40%ROA-38.98%Short Interest-Perf YTD87.71%
Book/sh2.98P/C-EPS next 5Y-ROE-43.94%52W High17.47 -9.10%Perf Year418.95%
Cash/sh2.98P/FCF-EPS past 3/5Y-ROIC-44.00%52W Low2.98 432.89%Perf 3Y-
Dividend Est.-EV/EBITDA-9.33Sales past 3/5Y146.62% -28.98%Gross Margin-546.17%Volatility3.09% 6.64%Perf 5Y-
Dividend TTM-EV/Sales238.85EPS Y/Y TTM33.47%Oper. Margin-2776.61%ATR (14)1.00Perf 10Y-
Dividend Ex-Date-Quick Ratio22.13Sales Y/Y TTM-60.00%Profit Margin-2554.14%RSI (14)63.87Recom2.00
Dividend Gr. 3/5Y-Current Ratio22.13EPS Q/Q10.87%SMA209.97%Beta1.87Target Price24.00
Payout0.00%Debt/Eq0.05Sales Q/Q-62.50%SMA5012.03%Rel Volume2.72Prev Close15.56
Employees259LT Debt/Eq0.05EarningsAug 06SMA20070.54%Avg Volume3.95MPrice15.88
IPO DateJul 16, 2020Option/ShortYes / YesEPS/Sales Surpr.-17.14% -50.00%Net Debt/EBITDA0.63Volume10,737,570Change2.06%
Analyst Ratings
DateActionAnalystRatingTarget
May-26-26ReiteratedH.C. Wainwright$25 → $28
May-26-26ReiteratedGuggenheimBuy$22 → $26
May-20-26ReiteratedBarclaysOverweight$17 → $27
May-19-26ReiteratedUBS$23 → $26
Apr-29-26ReiteratedH.C. Wainwright$19 → $25
Apr-28-26ReiteratedOppenheimerOutperform$14 → $18
Apr-28-26ReiteratedGoldman SachsBuy$22
Apr-28-26ReiteratedWells FargoOverweight$13 → $21
Mar-13-26ReiteratedGuggenheimBuy$22
Jan-26-26UpgradeOppenheimerPerform → Outperform$25 → $14
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue41510
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A17140
Gross Profit-1681210
Selling, General and Administrative Excl. Other585777
Research and Development296261319
Other Operating Expense-157-3-14
Operating Income-365-303-372
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-139-2613
Net Income Before Taxes-363-276-338
Income Taxes
000
Consolidated Net Income-363-276-338
Net Income From Continuing Operations-363-276-338
Net Income-363-276-338
EPS (Recurring)-3.89-1.61-2.36
EPS (Basic, Before Extraordinaries)-3.89-1.61-2.36
EPS (Diluted)-3.89-1.61-2.36
EBITDA-222-273-380
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio408.9197.01—
Gross Margin-4,200.0080.00100.00
Operating Margin-9,125.00-2,020.00-3,720.00
Net Margin-9,075.00-1,840.00-3,380.00
Shares Outstanding103172143
Market Capitalization1,6361,455—
Operating Lease Expense
———
Insider Trading Volume
$17.98$16.03$14.07$12.11$10.16● Close Price0.00K181.09K362.18K543.27K724.36KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Catinazzo ThomasChief Financial OfficerMay 14 '26Sale12.8617,717227,841195,178May 14 12:00 AM
Catinazzo ThomasChief Financial OfficerApr 28 '26Sale14.7997214,376212,895Apr 30 12:00 AM
Rahmer PeterSee remarksApr 28 '26Sale14.7975311,137275,857Apr 30 12:00 AM
Bergstrom Donald APresident, R&DApr 28 '26Sale14.791,49022,037418,557Apr 30 12:00 AM
Catinazzo ThomasChief Financial OfficerApr 09 '26Option Exercise5.223,60018,792215,667Apr 09 12:00 AM
Catinazzo ThomasChief Financial OfficerApr 09 '26Sale15.001,80027,000213,867Apr 09 12:00 AM
Catinazzo ThomasChief Financial OfficerApr 07 '26Sale13.0117,717230,498213,867Apr 09 12:00 AM
Catinazzo ThomasChief Financial OfficerMar 09 '26Sale10.0617,717178,233231,584Mar 11 12:00 AM
Catinazzo ThomasChief Financial OfficerJan 28 '26Sale8.451,69514,323249,301Jan 29 12:00 AM
Bergstrom Donald APresident, R&DJan 28 '26Sale8.452,68622,697420,047Jan 29 12:00 AM
Rahmer PeterSee remarksJan 28 '26Sale8.451,35411,441276,610Jan 29 12:00 AM
Rahmer PeterSee remarksJan 27 '26Sale7.6211,68489,032277,964Jan 29 12:00 AM
Bergstrom Donald APresident, R&DJan 27 '26Sale7.6218,895143,980422,733Jan 29 12:00 AM
Catinazzo ThomasChief Financial OfficerJan 27 '26Sale7.6213,820105,308250,996Jan 29 12:00 AM
Patel SanjivPresident and CEOJan 06 '26Sale7.8243,168337,574661,041Jan 07 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR